



10/506948  
PCT/GB03/00959

Rec'd PCT/

08 SEP 2004

#2

INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road

Newport  
South Wales  
NP10 8QQ


RECD 20 JUN 2003  
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

*R. Mahoney*

Dated

1 April 2003

**BEST AVAILABLE COPY**



11HAR02 2702276-2 000085  
P01/7700 0.00-0205593.7

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference

SJW/9179

2. Patent number  
(The)

0205593.7

09 MAR 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The University of Nottingham  
University Park  
Nottingham NG7 2RD  
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

437692.7 002

4. Title of the invention

"Treatment of Surfaces Populated by Bacteria"

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Stevens Hewlett & Perkins  
1 St. Augustine's Place  
Bristol BS1 4UD  
United Kingdom

Patents ADP number (if you know it)

1545002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

## Continuation sheets of this form

Description	11
Claim(s)	2
Abstract	-
Drawing(s)	10 + 10



10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11.

I/We request the grant of a patent on the basis of this application.

Signature Stevens Hewlett Perkins Date 08/03/02  
STEVEN'S HEWLETT & PERKINS

12. Name and daytime telephone number of person to contact in the United Kingdom

S J WILKINSON 0117 922 6007

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## TREATMENT OF SURFACES POPULATED BY BACTERIA

The present invention relates to a method of treating a surface populated by bacteria capable of producing a biofilm using secretions of *Lucilia sericata* larvae and to compositions useful in such a method.

Biofilms are biological films which develop and persist at surfaces. They may be found on the surfaces of industrial equipment where liquids are transported or processed, in plumbing systems, and on surfaces adjacent to such equipment or systems. They are often found on the surfaces of medical implants or devices inserted into the body. They may also form in areas of the body which are open to the air; in particular they may be found in wounds and on the lining of the lungs. A biofilm can be described as a bacterial population enclosed within a polysaccharide matrix which adheres to surfaces.

Biofilms are generally stable formations which are difficult to treat by conventional techniques. This is due to the protective nature of a polysaccharide biofilm matrix in which the micro-organisms are embedded. Conventional medicaments, such as antibiotics, are less effective either due to diffusion barriers or the altered metabolic state of micro-organisms in the biofilm.

Biofilm formation is thought to involve the production, by the micro-organisms, of diffusible signal molecules by a process known as quorum sensing. These molecules are thought to trigger production, by the micro-organisms, of exo-polysaccharides, exo-proteins and other secondary metabolites. Compounds which interfere with these molecular processes may inhibit biofilm formation and/or weaken an already formed biofilm.

*Pseudomonas aeruginosa* is one of the most common and problematical of infective bacteria. It is particularly problematical in that it forms biofilms which are difficult to treat with conventional antibiotics. Biofilm formation by *Pseudomonas aeruginosa* is problematical for patients with cystic fibrosis in whom it colonises the lungs causing infections which are difficult to treat and often ultimately fatal.

Efficient wound healing is a complex physiological process which involves many mechanisms including cell migration, growth factor secretion, angiogenesis, tissue remodelling and the intrinsic proteinase/antiproteinase balance of the wound contributing in concert and in an apparently staged manner to accelerate controlled tissue regeneration.

Wound care products are essential in modern medical practice, especially for the treatment of patients with chronic wounds or burns. Many different substances have previously been proposed as having activities which contribute to the healing of wounds. These previously proposed substances include streptokinase, collagenase and streptodornase (all obtained from bacterial sources), bromelain (from pineapples), plasmin and trypsin (obtained from cattle) and krill enzymes (obtained from crustacea). Clinical trial data indicate that such substances are only partially effective in promoting the healing of wounds.

The larvae (maggots) of the green bottle fly, *Lucilia sericata*, are known to have significant wound healing attributes as live organisms. Debridement treatment using the larvae of *Lucilia sericata* has become a widely accepted clinical practice. However, little has been reported in the literature about the way in which these larvae go about their task of cleaning wounds to an extent that conventionally intransigent wounds heal. Healing can be mechanical, biochemical or a combination of both. Our work shows that the effects of these larvae can be mimicked using extra-corporeal secretions.

Although efficacious, live larvae are unpleasant to many patients and the use of live larvae on wounds and the introduction of their crude secretions into wounds, which inevitably occurs when the larvae are used, are unacceptable to many patients and to many medical practitioners. The use of live organisms also increases the risk of allergic reactions in the patient.

The excretions/secretions (ES) of *Lucilia sericata* larvae are known to contain an enzyme which exhibits trypsin-like serine proteinase activity. This invention is based on the discovery that extra-corporeal ES also have the ability to break down the low molecular weight signalling molecules produced

by bacteria to determine the density of the bacterial population and, thus, disrupt the bacterial messaging network on which biofilm formation depends.

The present invention provides, in a first aspect, a method of treating a surface populated by a bacteria capable of producing a biofilm which comprises contacting the surface with a substance having N-acyl homoserine lactone degradant activity obtained from the secretions/excretions of *Lucilia sericata*. Typically, the bacteria capable of producing a biofilm is *Pseudomonas aeruginosa* or *Staphylococcus aureus*.

It is now becoming more generally accepted that the study of biofilm is more closely allied to the natural patterns of existence of bacteria than the more widely studied planktonic systems. Thomas S. et al, J. Tissue Viability, 1999 Vol 9 No.4 p127-132 reported antimicrobial activity of secretions of *Lucilia sericata* larvae on planktonic bacterial cells. We have not been able to reproduce these results. However, we have, in our experiments, found that under laboratory conditions the secretions of *Lucilia sericata* larvae have activity which prevents or reduces the formation of bacterial biofilms. In a wound situation the removal of bacterial biofilm would be advantageous in combating infection.

Our experiments have shown that exo-polysaccharides, which are formed as part of a bacterial biofilm, are removed by the action of the *Lucilia sericata* secretions. This effect is persuasive of the presence, in the secretions, of glycosidase activity.

The healing of a chronic wound has been shown to be impaired by the presence of a bacterial infection. The level of infection affects the balance between healing and chronicity. The bacterial contribution to wound hypoxia and pathological effects are an impediment to efficient healing.

It is known that diffusible low molecular weight signalling molecules allow individual bacteria to determine population density and thus to act in a concerted way when a "quorum" is assembled. This effect, generally known as "quorum sensing", is now known to control the production of virulence determinants in pathogens, thus ensuring a consolidated attack at a critical stage of infection. The low molecular weight signalling molecules (quorum

sensing molecules) are known to include N-acyl homoserine lactones, e.g. N-butanoyl L-homoserine lactone (BHL) and N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) from *Pseudomonas aeruginosa* (see Fig.1). Lactones also cause apoptosis in eukaryotic tissues therefore acting in opposition to the tissue regeneration required for wound healing. It is clear that the breakdown of such signalling molecules would reduce the ability of bacteria to mount an effective attack on host tissues. By our experiments we have shown that the secretions of *Lucilia sericata* larvae contain an activity which degrades BHL and, to a lesser extent, OdDHL. BHL is thought to be more active once bacteria form a biofilm. This activity has been found by us to be heat stable yet sensitive to phenylmethanesulphonyl fluoride (PMSF) and to 4-amidophenyl-methanesulphonyl fluoride (APMSF), both of which are known to inhibit serine protease and esterase activity.

The secretions from *Lucilia sericata* larvae may be collected by washing sterile larvae with phosphate buffered saline followed by filtering, under sterile conditions.

We have surprisingly found that the larval secretions when used in combination with a conventional antibiotic, such as tetracycline, have an antimicrobial effect which is greater than the individual effects of the larval secretions and antibiotic when used separately. There is, therefore, some synergy between these individual substances when used in combination. Thus, according to a further aspect, the present invention provides an antimicrobial composition comprising the secretions of *Lucilia sericata* larvae and one or more antibiotic compound. In a preferred embodiment, the antibiotic compound is tetracycline.

During the course of our investigations, we realised that many important components of larval secretions could be overlooked, as they might be inducible in haemolymph or other tissues by exposure to bacteria (as described by Hoffmann et al (1999) in *Drosophila melanogaster*) rather than constitutively expressed. Consequently, we have examined phenotypically-altered *L. sericata* larvae after exposure to bacteria *in vitro* for the production of antimicrobial compounds in the haemolymph.

The sterile secretions with or without the addition of a conventional antibiotic may be delivered onto a wound area using any known dermal delivery system or may be incorporated into a sterile support, such as a poultice, to be applied to a wound area as a dressing.

## **EXPERIMENTAL**

### **Method for preparation of *L. sericata* secretions**

Day old (1<sup>st</sup> instar) larvae of the greenbottle *Lucilia sericata* were purchased from the Surgical Materials Testing Laboratory (SMTL) Bridgend. These were raised under sterile conditions and all operations to collect the secretions were carried out using sterile equipment and in a laminar flow cabinet. Secretions were collected following the addition of 200µl phosphate buffered saline (PBS) to each universal (containing approx 200 larvae). The larvae were washed in the PBS for 20 min before the removal (sterile pipette), centrifugation (13,000 x g for 10 min) and freezing (-20°C) of the secretions. The larvae were allowed to rest for 40 min before a second wash and the process repeated for a third wash.

The collected secretions were assayed for protein content (BioRad protein assay) and protease activity (hydrolysis of fluorescein isothiocyanate labelled (FITC)-casein). The secretions were sterile filtered (22µm filter) and aliquotted ready for use and stored at -20°C.

### **1. Synergistic action of *L. sericata* ES with conventional antibiotics**

Minimum inhibitory concentration assays were used to determine the concentration of ES that would inhibit growth of planktonic bacteria in a 96 well plate – the growth being measured by increase in absorbance at 492 nm. In contrast with the observations of Thomas *et al.* (1999) the results showed that ES produced from *L. sericata* grown under sterile conditions had no antibiotic effect on growth of either gram +ve or gram -ve bacteria (*S. aureus* and *P. aeruginosa* respectively) (Figure 2).

Similarly, following absorbance at 492nm over a 24h period, the effect of ES and heat-denatured ES (boiled for 10min) was compared with the effect of the conventional antibiotic tetracycline on growth of *P. aeruginosa* (Figure



3). Growth was completely abolished by 10µg/ml tetracycline. By contrast the active ES showed a slight enhancement of growth (possibly due to biofilm stripping – see below Figure 4) measured by this method. However, using a sub-lethal level of tetracycline in combination with ES, there was found to be a synergistic effect between the two resulting in lower growth of the bacteria (Figure 4). This has also been confirmed using colony counts after 24h where the combination of tetracycline and active ES was found to reduce viable counts by one third.

Conclusion – *L. sericata* secretions alone did not have an antibiotic effect on bacterial growth under planktonic conditions, however there was a synergistic effect with the conventional antibiotic tetracycline.

## 2. Reduction in biofilm formation in the presence of *L. sericata* ES

It is now becoming more generally accepted that the study of biofilm is more closely allied to the natural patterns of existence of bacteria than the more widely used but inappropriate planktonic systems. In the wound situation the removal of bacterial biofilm would be advantageous in combating infection.

Reduction of biofilm formation in the presence of *L. sericata* ES was measured using the crystal violet method of O'Toole and Kolter (1999). Attached bacteria were quantified after 24h growth of culture in 96 well plates following removal of the planktonic bacteria (see section 3). Crystal violet dye was used to stain the attached bacteria before solubilisation and measurement of the absorbance of the stain at 540nm. A dose response reduction in biofilm formed was measured for *S. aureus* biofilm over 24h in the presence of *L. sericata* ES (Figure 5a). A similar reduction in *P. aeruginosa* biofilm formation was seen after incubation of glass coverslips in cultures grown in the presence of ES. Micro-colonies were visualised using BacLight stain (Figure 5b and 5c).

Conclusion – *L. sericata* secretions were active in preventing formation of bacterial film under laboratory conditions.

### 3. Glycosidase activity of *L. sericata* ES products

The recovery of cells from cultures grown under biofilm producing conditions revealed differences when the cultures were grown in the presence of *L. sericata* ES products. The culture was grown in 100µl aliquots in a 96 well microtitre plate. This has the effect of increasing the surface area of liquid in contact with the plastic well surface in comparison with flask grown culture, thus promoting the growth of biofilm. *P. aeruginosa* was inoculated from an overnight culture and grown to early exponential phase before dilution (1/2000) to give  $\sim 10^3$  cells per well. The culture was then grown in the presence of ES, inactivated ES (boiled 10min) or phosphate buffered saline (control). The culture was grown overnight at 37°C before collection together of each type of aliquot and centrifugation (13,000 x g for 10 min) to recover the cells. The results indicated (Figure 6) the presence of a "slime layer" in the control and denatured ES samples that was absent when cells were grown in the presence of active ES. The addition of an aliquot of active ES to sample D (denatured ES) followed by incubation overnight at 37°C resulted in the removal of the slime layer originally formed. We propose that the slime layer may consist of exo-polysaccharide formed as part of the biofilm and removed by the action of glycosidase in *L. sericata* ES. In the case of *P. aeruginosa* the exo-polysaccharide has been suggested to be alginate (a polymer consisting of poly guluronic and mannuronic acids).

Conclusion – The enzymatic removal of the exo-polysaccharide would compromise the ability of the bacteria to form an effective biofilm and therefore to establish an effective infection in the wound.

### 4. Inactivation of *P. aeruginosa* Quorum Sensing signalling molecules by a thermostable PMSF/APMSF-sensitive activity (lactonase) from *L. sericata* Excretory/Secretory Products (ES)

BHL and OdDHL may be quantified using thin layer chromatography (TLC) (RP18 F<sub>245S</sub> or RP2 UV<sub>254</sub> plates respectively). After chromatography

the position and amount of the signalling molecule may be revealed by their effect on biosensor organisms. The particular organisms used emit light when in contact with BHL or OdDHL. Therefore if the TLC plate is overlaid with soft agar containing the biosensor organism the position of the signalling molecule will be revealed by emission of light after a period of incubation. The intensity of the light emitted here is shown by converting to pseudo colour in which the most intense light shows as yellow with a gradation to the least intense – dark blue (Fig.7-side bar).

The effect of *L. sericata* secretions on BHL was examined by incubating the following:

1. 100µl ES (120µg/ml protein) + 100µM BHL
2. 100µl boiled ES (120µg/ml protein) + 100µM BHL
3. 100µl ES (120µg/ml protein) pre-incubated with APMSF (0.5mM)+100µM BHL
4. 100µl ES (120µg/ml protein) pre-incubated with PMSF (2mM)+100µM BHL
5. 100µM BHL in buffer (phosphate buffered saline)

After incubation for 6 hours, 1µl from each incubation was applied to an RP18F<sub>254S</sub> TLC plate and separated using 60%(v/v) methanol/water, before using the biosensor overlay to reveal the BHL as described above.

The results (Fig.7) demonstrate the effect of larval ES on degradation of BHL. The positive control (lane 5) showed light production from the BHL alone. There was a decrease in light production with BHL incubated in the presence of larval ES (lane 1) indicating degradation of the signalling molecule. This degradation was prevented by pre-incubation of the ES with phenylmethanesulphonyl fluoride (PMSF)(lane 4) and to a lesser extent 4-amidinophenyl-methanesulphonyl fluoride (APMSF)(lane 3)(inhibitors of serine protease activity). Boiling of the ES (lane 2) did not prevent degradation thus indicating thermal stability of the activity.

Further experiments confirmed a similar effect of ES on OdDHL (Figs 8 and 9) comparing samples taken at the start and end of a 6-hour incubation.

This time the TLC was carried out on RP2/UV<sub>254</sub> plates and with 45% (v/v) methanol/water. The degradation resulted in the appearance of a second species believed to signify ring opening of the OdDHL molecule. This remains to be confirmed by column chromatography (high performance liquid chromatography on a C18 column). Once again the degradation was stable to boiling but inhibited by PMSF and to a lesser extent APMSF.

Conclusion – *L. sericata* larval ES contains a thermostable activity sensitive to PMSF and APMSF which degrades BHL and OdDHL, two signalling molecules involved in *P. aeruginosa* biofilm formation and infection and therefore with implications for wound healing.

### 5. Induced anti-microbial activity in *L. sericata*

Sterile larvae of *L. sericata* were obtained from Surgical Materials Testing Laboratory SMTL (Princess of Wales Hospital, Bridgend CF31 1RQ). The larvae were grown on medium described by Sherman (1995), comprising decomposed pig's liver and bacto-agar, sterilised by autoclaving in a closed container which allowed the exchange of gas and moisture between the interior and exterior of the container but which prevented the entry, into the container, of bacteria. A thin layer of nutrient medium, for the larvae, was provided in the base of the container.

Sterile first instar larvae (200) were suspended in 200µl sterile phosphate buffered saline and transferred to the container. Growth was allowed under sterile conditions in a moisture chamber at 28°C for ~48h to allow establishment of the larvae. *Pseudomonas aeruginosa*, mutant PAO P47, was inoculated into 10ml Luria Bertani (LB) medium and grown overnight with shaking at 37°C. The container was inoculated with 1ml ( $10^8$  viable counts) of the culture and the larvae allowed to grow in the presence of the bacteria. After a further 48h the larvae were sacrificed and haemolymph collected after dorsal anterior incision. The haemolymph was microfuged (13,000 x g for 10 min) to remove cells.

Anti-microbial activity was assessed by the formation of bacteria-free plaques around wells containing 2µl haemolymph in a bacterial lawn of *E. coli*

D31. This plate was prepared by inoculating 1 $\mu$ l of culture (Absorbance 600nm = 0.4) into 7ml of molten (50°C) 1% LB agar containing 10 $\mu$ g/ml streptomycin and 5mg/ml lysozyme. This was formed in a sterile petri dish. The wells (8) were formed in a regular pattern equidistant from the edge of the plate using a template. The anti-microbial activity was assessed by comparison with plaques produced by 2 $\mu$ l Cecropin B (Sigma) at 100 $\mu$ g/ml, 10 $\mu$ g/ml, 1 $\mu$ g/ml and 0.1 $\mu$ g/ml (Fig.10). Haemolymph taken after 48h of induction by *P. aeruginosa* produced an antimicrobial plaque of 5mm diameter - greater than that produced by the 10 $\mu$ g/ml cecropin standard (4.25mm) but smaller than the 100 $\mu$ g/ml standard (8mm).

Conclusion – Anti-bacterial activity was found in *L. sericata* haemolymph after induction by exposure to *P. aeruginosa* during growth.

## REFERENCES

O'Toole, G.A. and Kolter, R. (1999) Initiation of biofilm formation in *Pseudomonas fluorescens* WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. *Molecular Microbiology* **28**: 449-461.

Sherman, R.A. and Tran, J.M. (1995) A simple, sterile food source for rearing the larvae of *Lucilia sericata* (Diptera; Calliphoridae). *Medical and Veterinary Entomology* **9**: 393-398.

Thomas, S., Andrews, A.M., Hay, N.P. and Bourgoise, S. (1999) The anti-microbial activity of maggot secretions: results of a preliminary study. *J. Tissue Viability* **9**: 127-132.

Hoffmann, J.A., Kefatos, F.C., Janeway, C.A. and Ezekowitz, R.A.B. (1999), Phylogenetic perspectives in innate immunity, *Science*; **284**; 1313-1318.

CLAIMS

1. A method of treating a surface populated by a bacteria capable of producing a biofilm which comprises contacting the surface with a substance having N-acyl homoserine lactone degradant activity obtained from the secretions/excretions of *Lucilia sericata*.
2. A method according to claim 1, wherein the surface is selected from metal surfaces, glass surfaces and the surfaces of plastics materials.
3. A method according to claim 1 or claim 2, wherein the surface is the surface of a medical device or implant.
4. A method according to claim 1, wherein the surface is a wound surface.
5. A method according to any one of claims 1 to 4, wherein the bacteria capable of producing a biofilm is *Pseudomonas aeruginosa* or *Staphylococcus aureus*.
6. A method according to any one of claims 1 to 5, wherein the substance is provided in a composition which additionally comprises one or more antibiotic compound.
7. A method according to claim 6, wherein the antibiotic compound is tetracycline.
8. An antimicrobial composition comprising secretions/excretions isolated from *Lucilia sericata* or analogues thereof and one or more antibiotic compound.
9. A composition according to claim 8, wherein the antibiotic compound is tetracycline.


10. An antimicrobial composition comprising, as an active component, a substance having N-acyl homoserine lactone-degradant activity isolated from secretions/excretions obtained from *Lucilia sericata* or analogues thereof together with a carrier or vehicle.
11. An antimicrobial composition comprising, as an active component, a serine proteinase isolated from secretion/excretions obtained from *Lucilia sericata* or analogues thereof together with a carrier or vehicle.
12. An antimicrobial composition comprising, as an active component, a glycosidase isolated from secretions/excretions obtained from *Lucilia sericata* or analogues thereof together with a carrier or vehicle.
13. An antimicrobial composition comprising, as an active component, a substance having cecropin-like activity isolated from secretions/excretions obtained from *Lucilia sericata* or analogues thereof together with a carrier or vehicle.
14. A composition according to any one of claims 10 to 13 which additionally comprises one or more antibiotic compound.
15. A composition according to claim 14, wherein the antibiotic compound is tetracycline.
16. An antimicrobial composition comprising cell-free haemolymph obtained from *Lucilia sericata* larvae grown in the presence of *Pseudomonas aeruginosa*, or one or more active constituent of said haemolymph or a synthetic analogue of such constituent.
17. A wound dressing comprising a composition according to any one of claims 8 to 16 together with a carrier.




Fig 1

Quorum Sensing Signalling Molecules from  
*Pseudomonas aeruginosa*

**BHL** (*N*-butanoyl *L*-homoserine lactone)



**OdDHL** (*N*-(3-oxododecanoyl) *L*-homoserine lactone))







Figure 2  
Effect of ES on planktonic growth of *P. aeruginosa* and *S. aureus*. Early log phase bacteria (~1000 organisms/well) were grown for 24h at 37°C in the presence of dilutions of ES in PBS in 96 well plates. Growth was measured by absorbance at 492nm.




Figure 3

Effect of ES, denatured ES or Tetracycline on planktonic growth of *P. aeruginosa* over 24h measured by absorbance at 492nm. The higher absorbance after 24h in the presence of ES compared with the denatured form may be due to enzymatic stripping of sessile organisms from the well.




Figure 4

Effect of 2.5 µg/ml tetracycline with active and denatured ES on planktonic growth of *P aeruginosa* over 24h measured by absorbance at 492nm.





Figure 5 Biofilm formation in the presence of *L. sericata* ES

a) Action of *L. sericata* ES on *Staphylococcus aureus* biofilm, quantified by monitoring absorbance at 540nm of solubilised crystal violet bound to adherent cells. b,c) Action of ES on growth of *Pseudomonas aeruginosa* biofilm on glass coverslips, visualised using Baclight™ stain b) represents control biofilm, after 20h growth. c) represents growth in the presence of *L. sericata* ES products (22µg/ml).




Figure 6

*Pseudomonas aeruginosa* 24h growth in biofilm producing conditions (100 $\mu$ l aliquots in a 96 well plate) containing active (ES) or denatured (D) *Lucilia sericata* secretions, collected together and microfuged (13,000 x g) for 10min.

The slime layer gave ~500 $\mu$ g/ml glucose (equivalent) concentration on testing for carbohydrate using concentrated phenol sulphuric.

The control (D) slime layer was subsequently removed by incubation (18h @ 37°C) with 2.5  $\mu$ g of active ES.

Degradation of BHL by *L. sericata* ES – Effect of boiling  
and of pre-incubation with inhibitors PMSF or APMSF




Figure 7  
Thin layer chromatography of 1 $\mu$ l of 100 $\mu$ M BHL after incubation for 6h  
with *L. sericata* ES (100 $\mu$ l - 120 $\mu$ g/ml total protein):  
1. ES  
2. Boiled ES  
3. ES pre-incubated with APMSF (0.5mM)  
4. ES pre-incubated with PMSF (2mM)  
5. BHL control in phosphate buffered saline.

Degradation of OdDHL by *L. sericata* ES – Effect of boiling.




Figure 8

Thin layer chromatography of 1 $\mu$ l of 100 $\mu$ M OdDHL after incubation with *L. sericata* ES (100 $\mu$ l - 120 $\mu$ g/ml total protein):

1. Boiled ES (t=0h)
2. Boiled ES (t=6h)
3. ES (t=0h)
4. ES (t=6h)



Degradation of OdDHL by *L. sericata* ES – Effect of pre-incubation with PMSF and APMSF





Figure 9

Thin layer chromatography of 1 $\mu$ l of 100 $\mu$ M OdDHL after incubation with *L. sericata* ES (100 $\mu$ l - 120 $\mu$ g/ml total protein):

1. ES pre-incubated with APMSF (0.5mM), t=0h
2. ES pre-incubated with APMSF (0.5mM), t=6h
3. ES pre-incubated with PMSF (2mM), t=0h
4. ES pre-incubated with PMSF (2mM), t=6h

Growth inhibition of *E. coli* D31 by haemolymph from *L. sericata* larvae taken after induction by *Pseudomonas aeruginosa*.



Anti-microbial  
activity induced by *P.*  
*aeruginosa* in larval  
haemolymph

Figure 10

Anti-microbial activity of *L. sericata* haemolymph after challenge by *P. aeruginosa*. Standards of the anti-microbial peptide Cecropin B (Sigma) were used. Clear plaques in the *E. coli* D31 lawn indicated anti-microbial activity. Diameter measurements give an indication of the anti-microbial peptide concentration in the sample.

1. Cecropin B 100µg/ml
2. Cecropin B 10µg/ml
3. Cecropin B 1µg/ml
4. Cecropin B 0.1µg/ml
5. Control 4h
6. *P. aeruginosa* 4h
7. *P. aeruginosa* 48h
8. Control 48h

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**